Impact of BMI on the Outcomes of Intensive LDL-C Lowering Therapy
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
A history of gestational diabetes is associated with increased risk for dyslipidemia.
The blood levels of non-high density lipoprotein cholesterol were found to have a strong association with the long-term risk for a cardiovascular disease event.
Pooled data from a systematic review and meta-analysis indicated that supplementation with whey protein reduced individual components of metabolic syndrome.
At the current price of the drug, and lacking sufficient mortality data, treating patients for longer periods of time with expensive PCSK9 inhibitors is likely to result only in large profits for the company.